EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Updates on Genetic Hearing Loss: From Diagnosis to Targeted Therapies

Yejin Yun, Sang-Yeon Lee

Journal of Audiology and Otology · 10.04.2024 · 28 (2) · 88-92

DOI: 10.7874/jao.2024.00157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Audiology and Otology, erschienen am 10.04.2024. Verfasst von Yejin Yun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seoul National University Hospital, National Research Foundation of Korea, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sensorineural hearing loss (SNHL) is the most common sensory disorder, with a high Mendelian genetic contribution. Considering the genotypic and phenotypic heterogeneity of SNHL, the advent of next-generation sequencing technologies has revolutionized knowledge on its genomic architecture. Nonetheless, the conventional application of panel and exome sequencing in real-world practice is being challenged by the emerging need to explore the diagnostic capability of whole-genome sequencing, which enables the detection of both noncoding and structural variations. Small molecules and gene therapies represent good examples of how breakthroughs in genetic understanding can be translated into targeted therapies for SNHL. For example, targeted small molecules have been used to ameliorate autoinflammatory hearing loss caused by gain-of-function variants of NLRP3 and inner ear proteinopathy with OSBPL2 variants underlying dysfunctional autophagy. Strikingly, the successful outcomes of the first-in-human trial of OTOF gene therapy highlighted its potential in the treatment of various forms of genetic hearing loss. clustered regularly interspaced short palindromic repeats (CRISPR)-based technologies are currently being developed for site-specific genome editing to treat human genetic disorders. These advancements have led to an era of genotype- and mechanism-based precision medicine in SNHL practice.

Schlagwörter

Stichwörter der Autor:innen

Genetic hearing lossGenetic therapyNext-generation sequencingSensorineural hearing lossSmall molecule

Autor:innen und Institutionen

  • Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea.
  • Sensory Organ Research Institute, Seoul National University Medical Research Center, Seoul, Korea.

Förderung

  • Seoul National University Hospital
  • National Research Foundation of Korea
  • Ministry of Education

Zitieren

APA

Yun, Y., & Lee, S. Y. (2024). Updates on Genetic Hearing Loss: From Diagnosis to Targeted Therapies. Journal of Audiology and Otology, 28(2), 88-92. https://doi.org/10.7874/jao.2024.00157

Vancouver

Yun Y, Lee SY. Updates on Genetic Hearing Loss: From Diagnosis to Targeted Therapies. Journal of Audiology and Otology. 2024;28(2):88-92. doi:10.7874/jao.2024.00157

BibTeX
@article{Yun2024,
  author = {Yun, Yejin and Lee, Sang-Yeon},
  title = {Updates on Genetic Hearing Loss: From Diagnosis to Targeted Therapies},
  journal = {Journal of Audiology and Otology},
  year = {2024},
  volume = {28},
  number = {2},
  pages = {88--92},
  doi = {10.7874/jao.2024.00157}
}
Kostenlos starten →